SynthesisArquivos brasileiros de cardiologia2019
Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Systematic Review and Updated Meta-Analysis of Risk Markers for Sudden Death.
Synthesis in Arquivos brasileiros de cardiologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Understanding the Mortality Trends in Patients With Ventricular Arrhythmias and Cardiomyopathy: A 25-Year Retrospective Analysis From 1999-2024.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026Observational
- Construction and verification of a diagnostic nomogram for heart failure in hypertrophic cardiomyopathy based on conventional clinical indicators: a case-control study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Maternal obesity decreases offspring lifespan.Molecular metabolism · 2026Article
- Prediction model for early left ventricular systolic dysfunction progression in hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2026Article
- High-frequency content within the QRS complex can predict ventricular tachyarrhythmias in hypertrophic cardiomyopathy.Journal of arrhythmia · 2025Article
- The Utility of Nuclear Imaging in Hypertrophic Cardiomyopathy: A Narrative Review.Journal of clinical medicine · 2025Review
- Association of liver fibrosis-4 index with adverse outcomes in hypertrophic cardiomyopathy patients.ESC heart failure · 2024Article
- Coronary microvascular dysfunction, arrythmias, and sudden cardiac death: A literature review.American heart journal plus : cardiology research and practice · 2024Article
- Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Functional significance of myocardial activity atEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Perspective from Fibroblasts.International journal of molecular sciences · 2023Review
- Sudden Cardiac Death: A Systematic Review.Cureus · 2023Review
- Global research trends of hypertrophic cardiomyopathy from 2000 to 2022: Insights from bibliometric analysis.Frontiers in cardiovascular medicine · 2023Article
- Imaging Targets to Visualize the Cardiac Immune Landscape in Heart Failure.Circulation. Cardiovascular imaging · 2023Review
- Article
- Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging.Heart failure reviews · 2021Review
- 8-Gingerol Ameliorates Myocardial Fibrosis by Attenuating Reactive Oxygen Species, Apoptosis, and AutophagyFrontiers in pharmacology · 2021Article
- A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.Circulation · 2020Article
- YBX-1 mediated sorting of miR-133 into hypoxia/reoxygenation-induced EPC-derived exosomes to increase fibroblast angiogenesis and MEndoT.Stem cell research & therapy · 2019Article
- Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment.Frontiers in pharmacology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is associated with sudden death (SD). Myocardial fibrosis is reportedly correlated with SD.
objectiveWe performed a systematic review with meta-analysis, updating the risk markers (RMs) in HCM emphasizing myocardial fibrosis.
methodsWe reviewed HCM studies that addressed severe arrhythmic outcomes and the certain RMs: SD family history, severe ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia (NSVT) on 24-hour Holter monitoring, abnormal blood pressure response to exercise (ABPRE), myocardial fibrosis and left ventricular outflow tract obstruction (LVOTO) in the MEDLINE, LILACS, and SciELO databases. We used relative risks (RRs) as an effect measure and random models for the analysis. The level of significance was set at p < 0.05.
resultsTwenty-one studies were selected (14,901 patients aged 45 ± 16 years; men, 62.8%). Myocardial fibrosis was the major RISK MARKER (RR, 3.43; 95% CI, 1.95-6.03). The other RMs, except for LVOTO, were also predictors: SD family history (RR, 1.75; 95% CI, 1.39-2.20), severe ventricular hypertrophy (RR, 1.86; 95% CI, 1.26-2.74), unexplained syncope (RR, 2.27; 95% CI, 1.69-3.07), NSVT (RR, 2.79; 95% CI, 2.29-3.41), and ABPRE (RR, 1.53; 95% CI, 1.12-2.08).
conclusionsWe confirmed the association of myocardial fibrosis and other RMs with severe arrhythmic outcomes in HCM and emphasize the need for new prediction models in managing these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.